Sign in

    Laura Hindley

    Research Analyst at Berenberg Bank

    Laura Hindley is an Equity Research Analyst at Berenberg Bank specializing in investment companies, with an emphasis on the biotechnology and real estate sectors. She covers prominent names such as HBM Healthcare Investments AG, International Biotechnology Trust plc, The Biotech Growth Trust plc, BB Biotech AG, and real estate firms including Aroundtown and Grand City Properties, regularly contributing to analysis with Berenberg's equity research team. Her analysis highlights include evaluating fund performance, where covered vehicles like HBMN have realized annualized returns exceeding 21% over the past decade and outperformed their benchmark by 6% per year. Based in London, Hindley joined Berenberg after establishing her expertise in equity research, and her professional activities are governed by UK and European financial regulators, with direct analyst contact details published in official Berenberg research.

    Laura Hindley's questions to NOVO NORDISK A S (NVO) leadership

    Laura Hindley's questions to NOVO NORDISK A S (NVO) leadership • Q1 2024

    Question

    Laura Hindley asked about the potential to apply once-monthly technology to other pipeline assets like amycretin or CagriSema and whether this technology influenced the development of the once-weekly GLP-1/GIP.

    Answer

    Martin Lange, Head of R&D, explained that the company is exploring several modalities for extended drug action. While the current once-monthly technology could potentially be applied elsewhere, the final decision for any asset will depend on a balance of efficacy and manufacturing scalability. The current trial is an initial exploration of the technology's potential.

    Ask Fintool Equity Research AI